<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04700436</url>
  </required_header>
  <id_info>
    <org_study_id>REMBRANDT</org_study_id>
    <nct_id>NCT04700436</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of EzetimiBe/Rosuvastatin in Diabetic Dislipidemia With Hypertriglyceridaemia</brief_title>
  <acronym>REMBRANDT</acronym>
  <official_title>A Multi-center, Randomized, Open-label, Active-controlled, Phase IV Clinical Trial to Evaluate the Efficacy and Safety of EzetimiBe/Rosuvastatin Diabetic Dislipidemia With Hypertriglyceridaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare and evaluate the effects of LDL-C and Triglyceride (TG) control on the first dose&#xD;
      Ezetimibe/Statin (Rosuvastatin 5 mg/Ezetimibe 10 mg) combination therapy compared to the&#xD;
      average dose Statin (Rosuvastatin 10 mg) monotherapy in patients with Type 2 diabetes with&#xD;
      hypertriglyceridemia (TG &gt; 200 mg/dL).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare and evaluate the effects of LDL-C and Triglyceride&#xD;
      (TG) control on the first dose Ezetimibe/Statin (Rosuvastatin 5 mg/Ezetimibe 10 mg)&#xD;
      combination therapy compared to the average dose Statin (Rosuvastatin 10 mg) monotherapy in&#xD;
      patients with Type 2 diabetes with hypertriglyceridemia (TG &gt; 200 mg/dL).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2020</start_date>
  <completion_date type="Anticipated">November 26, 2021</completion_date>
  <primary_completion_date type="Anticipated">May 28, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL-C change rate (percent, %)</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>To compare LDL-C change rate (percent, %) between test and control group</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Triglyceride (TG) change rate (percent, %)</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>To compare Triglyceride (TG) change rate (percent,%)between test and control group</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change rates (percent, %) of LDL-C and Triglyceride (TG)</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <description>To measure/compare Change rates (percent, %) of LDL-C and Triglyceride (TG) between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes (mg/dL) of Total cholesterol (TC), Triglyceride (TG), HDL-C, and non-HDL-C</measure>
    <time_frame>Baseline, 4 weeks, and 16 weeks</time_frame>
    <description>To measure/compare Changes (mg/dL) of Total cholesterol (TC), Triglyceride (TG), HDL-C, and non-HDL-C between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent (%) of subjects with a 50% or more reduction in LDL-C level</measure>
    <time_frame>4 weeks and 16 weeks</time_frame>
    <description>To measure/compare Percent (%) of subjects with a 50% or more reduction in LDL-C level between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent (%) of subjects with LDL-C below 70 mg/dL</measure>
    <time_frame>4 weeks and 16 weeks</time_frame>
    <description>To measure/compare Percent (%) of subjects with LDL-C below 70 mg/dL between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of lipoproteins (ApoA1, ApoB)</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>To measure/compare Changes of lipoproteins (ApoA1 (mg/dL), ApoB (mg/dL)) between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of lipoproteins (ApoB/ApoA1 ratio)</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>To measure/compare Changes of lipoproteins (ApoB/ApoA1 ratio) between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HOMA-IR</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>To measure/compare Change of HOMA-IR between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of HbA1C (percentage, %)</measure>
    <time_frame>Baseline, 4 weeks, and 16 weeks</time_frame>
    <description>To measure/compare Change of HbA1C (percentage, %) between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (mg/dL) of Fasting Plasma Glucose (FPG)</measure>
    <time_frame>Baseline, 4 weeks, and 16 weeks</time_frame>
    <description>To measure/compare Change (mg/dL) of Fasting Plasma Glucose (FPG) between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change (mg/dL) of hs-CRP</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>To measure/compare Change (mg/dL) of hs-CRP between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of plasma triglyceride (mg/dL), ApoB100 (mg/dL), and ApoB48 (mg/dL) levels at 30-minute, 1-, 2-, 3-, 4-, 5-, and 6-hour before and after FMC in subjects who perform FMC</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>To measure/compare Changes of plasma triglyceride (mg/dL), ApoB100 (mg/dL), and ApoB48 (mg/dL) levels at 30-minute, 1-, 2-, 3-, 4-, 5-, and 6-hour before and after FMC in subjects who perform FMC between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>On the graphs at 30-minute, 1-, 2-, 3-, 4-, 5-, and 6-hour before and after FMC in subjects who perform FMC, total Area Under the Curve (tAUC) of each plasma triglyceride (mg/dL), ApoB100 (mg/dL), and ApoB48 (mg/dL)</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>To measure/compare On the graphs at 30-minute, 1-, 2-, 3-, 4-, 5-, and 6-hour before and after FMC in subjects who perform FMC, total Area Under the Curve (tAUC) of each plasma triglyceride (mg/dL), ApoB100 (mg/dL), and ApoB48 (mg/dL) between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>To measure/compare Adverse event between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>To measure/compare Blood pressure between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse</measure>
    <time_frame>Baseline and 16 weeks</time_frame>
    <description>To measure/compare Pulse between test and control group</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Electrocardiogram (12-lead ECG)</measure>
    <time_frame>-4 weeks and 16 weeks</time_frame>
    <description>Number(%) of participants with Clinically Significant or Normal Electrocardiogram (12-lead ECG) findings after study drug administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Endocrine System Diseases</condition>
  <condition>Nutritional and Metabolic Diseases</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subject administered with Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subject administered with Suvast tablet 10 mg (Rosuvastatin 10 mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)</intervention_name>
    <description>IP&#xD;
Test drug: Rosuzet tablet 10/5 mg (Ezetimibe 10 mg/Rosuvastatin 5 mg)&#xD;
Control drug: Suvast tablet 10 mg (Rosuvastatin 10 mg)</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Test group</arm_group_label>
    <other_name>Suvast tablet 10 mg (Rosuvastatin 10 mg)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Screening (Visit 1) Inclusion Criteria&#xD;
&#xD;
          1. Korean men and women aged 40 to 75&#xD;
&#xD;
          2. Patients who have been diagnosed with type 2 diabetes based on clinical judgment and&#xD;
             satisfy diabetes diagnosis criteria&#xD;
&#xD;
          3. Those who have no history of statin administration or who are receiving low- and&#xD;
             moderate-intensity statin, and who have the following laboratory values on an empty&#xD;
             stomach&#xD;
&#xD;
               -  Low density lipoprotein-cholesterol (LDL-C) ≥ 100 mg/dL (direct measurement&#xD;
                  result)&#xD;
&#xD;
               -  200 mg/dL ≤ Triglyceride (TG) ≤ 499 mg/dL&#xD;
&#xD;
          4. Those with less than 9% HbA1C&#xD;
&#xD;
          5. Those who voluntarily agreed to participate in this clinical trial and signed a&#xD;
             written ICF&#xD;
&#xD;
        Randomization (Visit 2) Inclusion Criteria&#xD;
&#xD;
          1. Persons with compliance 80% or more during Suvast tablet 5 mg Run-in period and with&#xD;
             good TLC by investigator's judgment&#xD;
&#xD;
          2. LDL-C ≥ 70 mg/dL (direct measurement result) at baseline (visit 2)&#xD;
&#xD;
          3. Triglyceride (TG) ≥ 150 mg/dL at baseline (visit 2)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with hypersensitivity to the main ingredient (Ezetimibe or Rosuvastatin) and&#xD;
             ingredients of IP&#xD;
&#xD;
          2. Pregnant and lactating women, and women and men of childbearing potential who do not&#xD;
             agree to conduct appropriate contraception during clinical trial&#xD;
&#xD;
          3. Patients with Body Mass Index (BMI) &lt; 15 kg/ m2 or &gt; 35 kg/m2&#xD;
&#xD;
          4. Persons with the following medical history or surgical/interventional history&#xD;
&#xD;
               -  Atherosclerotic disease occurring within 24 weeks at screening&#xD;
&#xD;
               -  Myopathy including rhabdomyolysis&#xD;
&#xD;
               -  Patients who have had a history of drug or alcohol abuse, or who have met drug or&#xD;
                  alcohol abuse criteria within 1 year at screening&#xD;
&#xD;
               -  Major mental illness (depression, bipolar disorder, etc.)&#xD;
&#xD;
               -  Malignant tumor within 5 years at screening&#xD;
&#xD;
          5. Persons with the following comorbidities and laboratory abnormalities&#xD;
&#xD;
               -  CK ≥ 2 X ULN&#xD;
&#xD;
               -  Patients with severe hepatopathy (AST or ALT &gt; 5 X ULN)&#xD;
&#xD;
               -  Patients with unexplained persistent ALT elevation opinion or active liver&#xD;
                  disease&#xD;
&#xD;
               -  TSH (Thyroid stimulating hormone) &gt; 1.5 X ULN or those who do not maintain stable&#xD;
                  thyroid stimulating hormone level by investigator's judgment&#xD;
&#xD;
               -  Uncontrolled hypertension (greater than sitBP 160/100 mmHg at screening)&#xD;
&#xD;
               -  Renal disorder patients with severe renal failure (creatinine clearance (CLcr)&#xD;
&#xD;
          6. Those who have the following history of drug administration within 3 months at&#xD;
             screening&#xD;
&#xD;
               -  Non-statin lipid modulators&#xD;
&#xD;
               -  Foods or drugs that affect lipid control&#xD;
&#xD;
               -  Systemic steroids&#xD;
&#xD;
          7. Those who are expected to administer contraindication drugs during clinical trial,&#xD;
             including screening&#xD;
&#xD;
          8. Those who have persistent history of drinking within 1 week at clinical trial&#xD;
             participation or who are unable to perform TLC due to continuous drinking during&#xD;
             clinical trial&#xD;
&#xD;
          9. Patients with genetic problems such as galactose intolerance, Lapp lactase deficiency,&#xD;
             or glucose-galactose malabsorptioin&#xD;
&#xD;
         10. Those who received other IPs or investigational medical devices within 30 days at&#xD;
             screening&#xD;
&#xD;
         11. Patients judged to be ineligible to participate in clinical trial by investigator's&#xD;
             decision&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kyong Soo Park, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Kyong Soo Park, Dr.</last_name>
    <phone>+82-2-2072-2946</phone>
    <email>kspark@snu.ac.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Korea University Ansan Hospital</name>
      <address>
        <city>Ansan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji A Seo, Dr</last_name>
      <phone>+82-31-412-4275</phone>
      <email>seo-ji-a@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Bucheon</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ji Oh Mok, Dr</last_name>
      <phone>+82-32-621-5156</phone>
      <email>hanna@schmc.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Bucheon St. Mary's Hospital</name>
      <address>
        <city>Bucheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sung Rae Kim, Dr</last_name>
      <phone>+82-32-340-2025</phone>
      <email>kimsungrae@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Soon Chun Hyang University Hospital Cheonan</name>
      <address>
        <city>Cheonan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Wan Chung, Dr</last_name>
      <phone>+82-10-2708-8051</phone>
      <email>waan@schmc.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ho Chan Cho, Dr</last_name>
      <phone>+82-53-258-7726</phone>
      <email>hochan3632@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yeongnam University Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kyu-Chang Won, Dr</last_name>
      <phone>+82-53-620-3144</phone>
      <email>kcwon@med.yu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Junhwa Hong, Dr</last_name>
      <phone>+82-10-3230-5486</phone>
      <email>lammoth@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hosipital at Gangdong</name>
      <address>
        <city>Gangdong</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Inkyung Jung, Dr</last_name>
      <phone>+82-10-4283-9809</phone>
      <email>jik1016@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jung Hyun Noh, Dr</last_name>
      <phone>+82-10-4696-9323</phone>
      <email>jhnoh@paik.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Myongji Hospital</name>
      <address>
        <city>Goyang-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeahyuk Lee, Dr</last_name>
      <phone>+82-31-810-6048</phone>
      <email>jaehyugy93@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hanyang University Guri Hospital</name>
      <address>
        <city>Guri-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Chang Bum Lee, Dr</last_name>
      <phone>+82-31-560-2153</phone>
      <email>lekang@hanyang.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chosun University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sang Yong Kim, Dr</last_name>
      <phone>+82-10-9029-6762</phone>
      <email>diabetes@chosun.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hallym University Medical Center-Dongtan</name>
      <address>
        <city>Hwaseong-si</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunkyung Hong, Dr</last_name>
      <phone>+82-31-8086-2490</phone>
      <email>hegletter@hanmail.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inha University Hospital</name>
      <address>
        <city>Inchon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>So Hun Kim, Dr</last_name>
      <phone>+82-10-3325-8058</phone>
      <email>shoney@inha.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Pusan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sang Soo Kim, Dr</last_name>
      <phone>+82-51-240-7837</phone>
      <email>drsskim7@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sin Gon Kim, Dr</last_name>
      <phone>+82-2-920-5890</phone>
      <email>K50367@korea.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hye-jin Yoo, Dr</last_name>
      <phone>+82-2-2626-3052</phone>
      <email>deisy21@naver.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kyung Hee University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Suk Chon, Dr</last_name>
      <phone>+82-2-958-8843</phone>
      <email>imdrjs@kju.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jae Hyeon Kim, Dr</last_name>
      <phone>+82-10-4945-1580</phone>
      <email>jaehyeonmd.kim@samsung.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kyong Soo Park, Dr</last_name>
      <phone>+82-2-2072-2946</phone>
      <email>kspark@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St.Mary</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>SeungHwan Lee, Dr</last_name>
      <phone>+82-2-2258-6069</phone>
      <email>hwanx2@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Yeouido St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hyuk Sang Kwon, Dr</last_name>
      <phone>+82-2-3779-1039</phone>
      <email>drkwon@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System, Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shinae Kang, Dr</last_name>
      <phone>+82-2-2019-3335</phone>
      <email>shinae95@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yonsei University Health System, Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Byung Wan Lee, Dr</last_name>
      <phone>+82-10-9460-0338</phone>
      <email>bwanlee@yuhs.ac</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hae Jin Kim, Dr</last_name>
      <phone>+82-10-2788-3090</phone>
      <email>jinkim@aumc.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seuhg Hyun Ko, Dr</last_name>
      <phone>+82-31-881-8900</phone>
      <email>kosh@catholic.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gachon University, Donginchoen Gil Hospital</name>
      <address>
        <city>Sŏngnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ki Young Lee, Dr</last_name>
      <phone>+82-32-460-2610</phone>
      <email>kylee@gilhospital.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Sŏngnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sung Hee Choi, Dr</last_name>
      <phone>+82-31-787-7029</phone>
      <email>shchoimd@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>October 5, 2020</study_first_submitted>
  <study_first_submitted_qc>January 6, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 7, 2021</study_first_posted>
  <last_update_submitted>January 6, 2021</last_update_submitted>
  <last_update_submitted_qc>January 6, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Kyong Soo Park</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Dyslipidemias</mesh_term>
    <mesh_term>Metabolic Diseases</mesh_term>
    <mesh_term>Hypertriglyceridemia</mesh_term>
    <mesh_term>Endocrine System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

